Financial Performance Highlights (Q2 FY27)

  • Consolidated Total Revenue: ₹1,019.4 crores (QoQ: ₹794 crores in Q1FY27; YoY: ₹1,463 crores in Q2FY26).
  • EBITDA including other income: ₹310 crores.
  • EBITDA Margin: 30.4%.
  • Consolidated Profit After Tax (PAT): ₹202.6 crores (QoQ: ₹206.5 crores in Q1FY27).
  • The quarter-on-quarter revenue increase was primarily driven by strong performance in the international formulation business. The year-on-year decline was largely attributable to lower lenalidomide revenue, partially offset by growth in the base business including subsidiaries.

Associate Company - Adcock Ingram Holding Limited (South Africa)

  • Revenue for the quarter: ₹1,344 crores.
  • Profit After Tax for the quarter: ₹80.5 crores.
  • In July 2026, NATCO acquired an additional 13.25% stake in Adcock Ingram, taking its total holding to 49%.
  • NATCO's share of profit based on 49% holding as of 30 September 2026 was ₹29.2 crores, after adjustment for purchase price allocation.
  • A dividend of ₹78 crores was received from Adcock during the period.
  • The company estimates a steady-state annual PAT contribution from its 49% stake to be approximately ₹55-60 crores, after accounting for amortization.

Segment-wise Performance

  • Domestic Formulation Business Revenue: ₹145 crores. The management clarified that the base domestic run rate is ₹130-135 crores, with the higher Q2 figure including a one-time stocking quantity of Semaglutide for partners.
  • Brazil Business Revenue: ₹121 crores, representing 66% growth.
  • Crop Health Sciences (Agri-business): Reported a marginal profit of ~₹10 lakhs for the quarter, compared to a loss in Q1. The business is battling credit-related provisions and El Niño effects but expects 15-20% growth for the year.

Capital Structure & Fundraising

  • A rights issue was completed last month (October 2026), resulting in a 10% equity dilution.
  • The primary end-use of the proceeds is to reduce debt raised for the Adcock acquisition and to fund potential future acquisitions.
  • As of the call date, the company reported net cash of approximately ₹2,250 crores after repaying all debt.
  • A dividend was declared, consistent with the company's historical policy, and is not linked to the recent fundraising.

Guidance & Outlook

  • Management provided FY27 PAT guidance of ₹775-800 crores, an improvement over the initial guidance of ₹700-750 crores.
  • The guidance includes an expected EBITDA loss of ~₹20 crores from the Crop Health Sciences segment.
  • The base business (excluding one-time exclusivity gains) is expected to grow at 10-15% in FY28.
  • R&D spend for FY27 is expected to be 8-10% of sales, amounting to approximately ₹300-350 crores.
  • Annual Capex run rate is typically ₹350-400 crores, focused on upgrading facilities in Chennai, Mekaguda, and Nagarjuna Sagar, including a new oncology line and a cartridge line for internal Semaglutide production.

Product Pipeline & Launches

  • Pomalidomide: Had a shared first-to-file (FTF) status with 5-6 competitors. The price erosion was steep, resulting in a less substantial earnings bump than anticipated.
  • Upcoming US Launches (Subject to approval and legal challenges): Carfilzomib (60mg strength has shared FTF; one lower strength has sole FTF), Trabectedin (one of two FTFs), and Olaparib (for Brazil and Canada).
  • Semaglutide (India): The company has an estimated 5-6% volume share and ~3% value share in the Indian market. Pricing is described as "really bad" due to intense competition, and the business is not currently profitable.
  • Other Products: Risdiplam is performing well domestically. The US filing for Semaglutide is ongoing, with queries being answered. Imbruvica is settled and approved for launch in 30 months.
  • NRC-2694: Phase-I data is complete; the company is re-evaluating its Phase-II strategy. No commercialization timeline provided.

Strategic Updates

  • Adcock Ingram: A new CEO, Mr. Rhulani (ex-Pfizer), has been appointed to strengthen the prescription business. The company has filed multiple products for regulatory approval in South Africa, with launches expected in the next 1.5-2 years.
  • Crop Health Sciences Demerger: The process has been delayed by 4-6 months due to the recent rights issue altering the capital structure. The company must resubmit filings to SEBI and now expects the demerger to be completed by mid-calendar year 2027.
  • Acquisition Strategy: The company is actively looking for acquisition opportunities and is in serious discussions for one transaction. The strategy focuses on "value for money" rather than a specific target P/E.
  • Investment in eGenesis: NATCO holds a substantial single-digit stake (investment <$25 million) in eGenesis, a company developing xenotransplantation (pig-to-human kidney transplant). Monetization options include securing a license for the India market or an eventual IPO of eGenesis. Data readouts are expected in the next 12 months.

Management Commentary

  • The CEO, Mr. Rajeev Nannapaneni, addressed concerns about the company's stock performance and P/E multiple, characterizing NATCO's model as "high-risk, high-return" with inherent earnings lumpiness due to exclusivity-driven revenues.
  • He emphasized that communication with investors is regular and that the company's strategy remains focused on creating long-term value through strategic investments and pipeline development, rather than managing short-term stock price movements.